CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

BACKGROUND: CA-125 as a tumour progression criterion in relapsing ovarian cancer (ROC) trials remains controversial. CALYPSO is a large randomised trial incorporating CA-125 (GCIG criteria) and symptomatic deterioration in addition to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Alexandre, J, Brown, C, Coeffic, D, Raban, N, Pfisterer, J, Mäenpää, J, Chalchal, H, Fitzharris, B, Volgger, B, Vergote, I, Pisano, C, Ferrero, A, Pujade-Lauraine, E
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3322951/
https://ncbi.nlm.nih.gov/pubmed/22240800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.593
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars